◎ Sugi Atlas

Atlas / Drug / Calcium

Calcium

drug
On this page

Summary

Calcium (CHEMBL1200496) is an approved small molecule targeting KCNN1, KCNN2, and KCNN3; indicated across 49 conditions including colorectal adenoma and postmenopausal osteoporosis.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • Targets: 43 (KCNN1, KCNN2, KCNN3…)
  • Indications: 49 conditions
  • Clinical trials: 266
  • Chemistry: 40.08 Da · Ca

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1200496
NameCalcium
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID5460341
ChEBICHEBI:22984
Molecular formulaCa
Molecular weight40.08
InChIKeyOYPRJOBELJOOCE-UHFFFAOYSA-N

SMILES: [Ca]

IUPAC name: calcium

Pharmacological roles (ChEBI): macronutrient.

Also known as: Calcium, CALCIUM

Patent coverage: 19,057 distinct patent families (39,957 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
5-HT3ANegative
KCNN1KCa2.1Agonist6.521.5%Q92952
KCNN2KCa2.2Agonist6.50%Q9H2S1
KCNN3KCa2.3Agonist6.50%Q9UGI6
KCNN4KCa3.1Agonist70.2%O15554
KCNT1KNa1.1Antagonist6.51.2%Q5JUK3
TRPC2
TRPC5TRPC56.20%Q9UL62
TRPM2TRPM20.4%O94759
TRPM4TRPM4Agonist6.30.5%Q8TD43
TRPM5TRPM5Agonist6.20.2%Q9NZQ8
TRPM6TRPM65.320.1%Q9BX84
PKD2TRPP16Q13563
PKD2L1TRPP2Agonist0%Q9P0L9
CASRCaS receptorFull agonist2.40.1%P41180
ZACNZACAntagonist2.037%Q401N2
ANO1CaCCActivation1.2%Q5XXA6
GJE1Cx231.4%A6NN92
GJB7Cx250%Q6PEY0
GJB2Cx260.2%P29033
GJB6Cx300.2%O95452
GJC3Cx30.22.2%Q8NFK1
GJB4Cx30.30.4%Q9NTQ9
GJB3Cx310.5%O75712
GJB5Cx31.10.1%O95377
GJD3Cx31.91.6%Q8N144
GJB1Cx320.1%P08034
GJD2Cx360%Q9UKL4
GJA4Cx370.1%P35212
GJA5Cx401.2%P36382
GJD4Cx40.10.6%Q96KN9
GJA1Cx431.6%P17302
GJC1Cx453.1%P36383
GJA3Cx4618.5%Q9Y6H8
GJC2Cx470%Q5T442
GJA8Cx500.4%P48165
GJA9Cx590.3%P57773
GJA10Cx62Q969M2
ITPR1IP3R11.4%Q14643
ITPR2IP3R20.2%Q14571
ITPR3IP3R31.1%Q14573
RYR1RyR11%P21817
RYR2RyR20.3%Q92736
RYR3RyR30%Q15413
NALCNNALCN3.880%Q8IZF0

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 43 target gene(s): KCNN1, KCNN2, KCNN3, KCNN4, KCNT1, TRPC5, TRPM2, TRPM4, TRPM5, TRPM6, PKD2, PKD2L1, CASR, ZACN, ANO1, GJE1, GJB7, GJB2, GJB6, GJC3, GJB4, GJB3, GJB5, GJD3, GJB1, GJD2, GJA4, GJA5, GJD4, GJA1, GJC1, GJA3, GJC2, GJA8, GJA9, GJA10, ITPR1, ITPR2, ITPR3, RYR1, RYR2, RYR3, NALCN.

Top Reactome pathways

89 total, by targets touching each:

PathwayTargetsGenes
Gap junction assembly19GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJD2, GJD3, GJD4
Muscle contraction6ITPR1, ITPR2, ITPR3, RYR1, RYR2, RYR3
Cardiac conduction6ITPR1, ITPR2, ITPR3, RYR1, RYR2, RYR3
Ion homeostasis6ITPR1, ITPR2, ITPR3, RYR1, RYR2, RYR3
Stimuli-sensing channels5ANO1, NALCN, RYR1, RYR2, RYR3
TRP channels5TRPC5, TRPM2, TRPM4, TRPM5, TRPM6
Transport of small molecules5ANO1, NALCN, RYR1, RYR2, RYR3
Ion channel transport5ANO1, NALCN, RYR1, RYR2, RYR3
Neuronal System4KCNN1, KCNN2, KCNN3, KCNN4
Ca2+ activated K+ channels4KCNN1, KCNN2, KCNN3, KCNN4
Potassium Channels4KCNN1, KCNN2, KCNN3, KCNN4
Signal Transduction4CASR, ITPR1, ITPR2, ITPR3
Disease4ANO1, ITPR1, ITPR2, ITPR3
Signaling by GPCR4CASR, ITPR1, ITPR2, ITPR3
GPCR downstream signalling4CASR, ITPR1, ITPR2, ITPR3
G alpha (q) signalling events4CASR, ITPR1, ITPR2, ITPR3
G alpha (i) signalling events4CASR, ITPR1, ITPR2, ITPR3
Infectious disease4ANO1, ITPR1, ITPR2, ITPR3
Hemostasis3ITPR1, ITPR2, ITPR3
Opioid Signalling3ITPR1, ITPR2, ITPR3
G-protein mediated events3ITPR1, ITPR2, ITPR3
PLC beta mediated events3ITPR1, ITPR2, ITPR3
Electric Transmission Across Gap Junctions3GJA10, GJC1, GJD2
Effects of PIP2 hydrolysis3ITPR1, ITPR2, ITPR3
Adaptive Immune System3ITPR1, ITPR2, ITPR3
Elevation of cytosolic Ca2+ levels3ITPR1, ITPR2, ITPR3
Metabolism3ITPR1, ITPR2, ITPR3
DAG and IP3 signaling3ITPR1, ITPR2, ITPR3
Integration of energy metabolism3ITPR1, ITPR2, ITPR3
Innate Immune System3ITPR1, ITPR2, ITPR3

Dominant GO biological processes

GO termTargets
transmembrane transport34
monoatomic ion transmembrane transport24
monoatomic ion transport21
cell-cell signaling21
cell communication21
calcium ion transmembrane transport14
calcium ion transport13
monoatomic cation transmembrane transport10
protein homotetramerization10
potassium ion transmembrane transport9
calcium-mediated signaling9
release of sequestered calcium ion into cytosol8
potassium ion transport7
gap junction assembly7
sodium ion transmembrane transport5

Indications & clinical

Indications

49 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
colorectal adenoma3MONDO:0005484EFO:0005406
postmenopausal osteoporosis3MONDO:0008159EFO:0003854
osteoporosis3MONDO:0005298EFO:0003882
obesity disorder3MONDO:0011122EFO:0001073
leukemia3MONDO:0005059EFO:0000565
lymphoma3MONDO:0005062EFO:0000574
polycystic ovary syndrome3MONDO:0008487EFO:0000660
juvenile idiopathic arthritis3MONDO:0011429EFO:0002609
bone fracture3MONDO:0005315EFO:0003931
hip fracture3MONDO:0005327EFO:0003964
colorectal neoplasm3MONDO:0005335EFO:0004142
bone Paget disease3MONDO:0005382EFO:0004261
hyperprolactinemia3MONDO:0005804EFO:0007319
colorectal carcinoma3MONDO:0024331EFO:1001951
breast neoplasm3MONDO:0021100EFO:0003869
colonic neoplasm3MONDO:0005401EFO:0004288
myocardial ischemia3MONDO:0024644EFO:1001375
allergic disease3MONDO:0005271MONDO:0005271
ovarian hyperstimulation syndrome3MONDO:0011972MONDO:0011972
cardiovascular disorder3MONDO:0004995EFO:0000319
coronary artery disorder3MONDO:0005010EFO:0001645
pulpitis3MONDO:0006937EFO:1001139
preeclampsia2MONDO:0005081EFO:0000668
exocrine pancreatic carcinoma2MONDO:0005192EFO:0002618
heart failure2MONDO:0005252EFO:0003144
heart disorder2MONDO:0005267EFO:0003777
dental caries2MONDO:0005276EFO:0003819
primary hyperparathyroidism2MONDO:0010837EFO:0008519
hypoparathyroidism2MONDO:0001220EFO:0009451
giant cell tumor2MONDO:0002171MONDO:0002171
bone giant cell tumor2MONDO:0005674EFO:0007176
Parkinson disease2MONDO:0005180MONDO:0005180
osteogenesis imperfecta2MONDO:0019019MONDO:0019019
bipolar disorder2MONDO:0004985MONDO:0004985
neoplasm2MONDO:0005070MONDO:0004992
rectal cancer2MONDO:0006519EFO:1000657
chronic kidney disease1MONDO:0005300EFO:0003884
vitamin D deficiency1MONDO:0100471EFO:0003762
hypertensive disorder1MONDO:0005044EFO:0000537
HIV infectious disease0MONDO:0005109EFO:0000764
injury0MONDO:0021178EFO:0000546

8 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 266.

Phase distribution

PhaseTrials
Not specified111
PHASE347
PHASE237
PHASE433
PHASE122
PHASE1/PHASE26
PHASE2/PHASE35
EARLY_PHASE15

Top trials by phase / activity

NCTPhaseStatusTitle
NCT05058976PHASE4ACTIVE_NOT_RECRUITINGRomosozumab Use to Build Skeletal Integrity
NCT05096195PHASE4ACTIVE_NOT_RECRUITINGPRevEnting FracturEs in REnal Disease - 1
NCT07072923PHASE4NOT_YET_RECRUITINGAntibiotic Impregnated Beads in Osteomyelitis
NCT07419854PHASE4RECRUITINGRestoring Facial Volume After GLP-1 Weight Loss With Radiesse
NCT00160264PHASE4COMPLETEDStudy to Investigate if Adding Lactulose to Vitamin D and Calcium Has an Effect on the Preservation of Bone in Postmenopausal Women
NCT00460733PHASE4COMPLETEDSOLID-Effect of Risedronate Sodium at Distal Radius in Colle’s Fracture.
NCT00486772PHASE4COMPLETEDSevelamer, Fetuin-A and Endothelial Dysfunction in CKD
NCT00668200PHASE4COMPLETEDImpact on Reducing the Incidence of Low Serum Calcium by Providing Educational Materials on the Need to Take Daily Supplemental Calcium and Vitamin D to Patients With Paget’s Disease Treated With Reclast®
NCT00668330PHASE4COMPLETEDSteroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus
NCT00729651PHASE4COMPLETEDEfficacy and Safety Study of Fosamax Plus D in Postmenopausal Women With Osteoporosis (0217A-263)
NCT00887354PHASE4COMPLETEDA Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture
NCT00949832PHASE4COMPLETEDVitamin D and Genetics in Nutritional Rickets
NCT01225354PHASE4COMPLETEDInjectable Filler for Cheek Flattening
NCT01350934PHASE4COMPLETEDA Study to Evaluate Alendronate Sodium /Vitamin D3 Combination Tablets(FOSAMAX PLUS) Versus Calcitriol in the Treatment of Osteoporosis in Postmenopausal Women in China (MK-0217A-264)
NCT01427907PHASE4COMPLETEDEquivalence of Calcium Acetate Oral Solution and Sevelamer Carbonate Tablets in Hemodialysis Patients
NCT01578434PHASE4COMPLETEDRole of Calcium And Vitamin D In Nutritional Rickets And It’s Management
NCT01631305PHASE4COMPLETEDLevothyroxine for Children With Euthyroid Sick Syndrome
NCT01709110PHASE4COMPLETEDVERtebral Fracture Treatment Comparisons in Osteoporotic Women
NCT01753856PHASE4COMPLETEDEffects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis
NCT02090400PHASE4COMPLETEDSwitching From Oral Bisphosphonates to Bazedoxifene to Evaluate Effects on Bone Mineral Density in Postmenopausal Women
NCT02169570PHASE4UNKNOWNEffect of Supplementary Vitamin D in Patients With Diabetes Mellitus and Pulmonary Tuberculosis
NCT02338687PHASE4COMPLETEDLow Dose Calcium to Prevent Preeclampsia
NCT02416271PHASE4COMPLETEDThe Forteo Alendronate Comparator Trial
NCT02589600PHASE4COMPLETEDZoledronic Acid for Osteoporotic Fracture Prevention (ZEST II)
NCT02602704PHASE4COMPLETEDEffectiveness of Bazedoxifene for Prevention of Glucocorticoid-induced Bone Loss in RA Patients
NCT02753283PHASE4COMPLETEDPreventing Osteoporosis Using Denosumab
NCT03158246PHASE4UNKNOWNGeneric Zoledronic Acid Versus Original Zoledronic Acid in Postmenopausal Osteoporotic Women
NCT04255992PHASE4COMPLETEDShort Term Cardiovascular Effects and Oxidative Status of Calcium and Vitamin D Supplementation of Postmenopausal Hypertensive Blacks Women
NCT04485039PHASE4COMPLETEDDrug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders
NCT05203588PHASE4UNKNOWNEffects of Denosumab on Bone Fusion in Osteoporotic Patients After Lumbar Fusion
NCT05661942PHASE4COMPLETEDDiltiazem in the Treatment of Atrial Fibrillation or Atrial Flutter With Rapid Ventricular Rate
NCT05884372PHASE4COMPLETEDEfficacy and Safety of Combination Denosumab With Eldecalcitol for Postmenopausal Women With Osteoporosis.(ESCORT)
NCT06494007PHASE4COMPLETEDRole of IV Calcium to Prevent Diltiazem-related Hypotension
NCT07366086PHASE3RECRUITINGPediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta
NCT00000534PHASE3COMPLETEDCalcium for Pre-Eclampsia Prevention (CPEP)
NCT00000611PHASE3COMPLETEDWomen’s Health Initiative (WHI)
NCT00022087PHASE3COMPLETEDZoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer
NCT00030238PHASE3COMPLETEDSupplemental Calcium in Overweight People
NCT00048061PHASE3COMPLETEDMOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis
NCT00051636PHASE3COMPLETEDSafety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget’s Disease of Bone, Including an Extended Observation Period

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

58 molecules share ≥1 primary target. Top 58 by shared-target count:

MoleculeSourceStatusShared targets
TubocurarinePubChemApprovedKCNN2, KCNN3, ZACN
CLOTRIMAZOLEChEMBL + PubChemPhase 4 (approved)KCNN4, TRPM2
KANAMYCINChEMBL + PubChemPhase 4 (approved)GJA1, GJB2
CEPHARANTHINEChEMBLPhase 2KCNN2, KCNN3
Oxolinic AcidPubChemApprovedRYR2, RYR3
RiluzolePubChemApprovedKCNN3, KCNN4
ADENOSINEChEMBL + PubChemPhase 4 (approved)TRPM2
CINACALCETChEMBL + PubChemPhase 4 (approved)CASR
ECONAZOLEChEMBL + PubChemPhase 4 (approved)TRPM2
NITAZOXANIDEChEMBL + PubChemPhase 4 (approved)ANO1
QUINIDINEChEMBL + PubChemPhase 4 (approved)KCNT1
TOFACITINIBChEMBL + PubChemPhase 4 (approved)TRPM6
BEPRIDILChEMBLPhase 4 (approved)KCNT1
COPPERChEMBLPhase 4 (approved)TRPM2
DEQUALINIUM CHLORIDEChEMBLPhase 4 (approved)KCNN3
NICLOSAMIDEChEMBLPhase 4 (approved)ANO1
QUERCETINChEMBL + PubChemPhase 3 (approved)TRPC5
ENCALERETChEMBLPhase 3CASR
EVOCALCETChEMBLPhase 3CASR
SENICAPOCChEMBLPhase 3KCNN4
ALADORIANChEMBLPhase 2RYR2
FENDILINEChEMBLPhase 2CASR
FLUFENAMIC ACIDChEMBLPhase 2TRPM2
RONACALERETChEMBLPhase 2CASR
SB-423562ChEMBLPhase 2CASR
TECALCETChEMBLPhase 2CASR
TG100-115ChEMBLPhase 2TRPM6
ZERENCOTREPChEMBLPhase 2TRPC5
AfatinibPubChemApprovedTRPM6
AxitinibPubChemApprovedTRPM6
BosutinibPubChemApprovedTRPM6
CaffeinePubChemApprovedRYR2
ChlorzoxazonePubChemApprovedKCNN4
CrizotinibPubChemApprovedTRPM6
DantrolenePubChemApprovedRYR2
ErlotinibPubChemApprovedTRPM6
FedratinibPubChemApprovedTRPM6
GefitinibPubChemApprovedTRPM6
GenisteinPubChemApprovedTRPC5
ImatinibPubChemApprovedTRPM6
LapatinibPubChemApprovedTRPM6
LoxapinePubChemApprovedKCNT1
Mefenamic AcidPubChemApprovedTRPM2
MiconazolePubChemApprovedTRPM2
MidostaurinPubChemApprovedTRPM6
NadidePubChemApprovedTRPM2
NeratinibPubChemApprovedTRPM6
NilotinibPubChemApprovedTRPM6
PazopanibPubChemApprovedTRPM6
ProgesteronePubChemApprovedTRPC5
QuizartinibPubChemApprovedTRPM6
RosiglitazonePubChemApprovedTRPC5
RuxolitinibPubChemApprovedTRPM6
SelumetinibPubChemApprovedTRPM6
SorafenibPubChemApprovedTRPM6
SunitinibPubChemApprovedTRPM6
tryptophanPubChemApprovedCASR
VandetanibPubChemApprovedTRPM6

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot